METHODS:It was a randomized, double-blind, placebo-controlled trial conducted in 36 allergic rhinitis patients who suffer vitamin D deficiency; age 18-49 years. The intervention based on patient treated with SCIT–calcitriol 0.5 mcg/day and SCIT–placebo as the control group on immunotherapy build-up phase. All groups evaluated at baseline, week 8 and week 15 for proportion CD4+CD25+CD127low regulatory T-cells using flow cytometry, IL-10, and TGF-β using ELISA. Nasal symptoms score using Visual Analoq Scale. The Mann Whitney test, Friedman test and post-hoc test using Wilcoxon used for statistical analysis.
RESULTS: The proportions of CD4+CD25+CD127low regulatory T-cells significantly increased in the intervention group compared with control (p=0.04) in week 8. There was a significant and positive tren in the increase of anti -inflammatory cytokines in the intervention group at week 8, particulary in IL-10 (p=0.035) and TGF-β (p=0.001), whereas control groups show after the week 15. The decrease in nasal symptoms score did not differ significantly between groups (p>0.05).
CONCLUSIONS: Immunologic outcomes changes start in week 8 in SCIT with 1.25-Dihidroxyvitamin D3 group. However, clinical improvement was mostly similar between groups. 1.25-Dihidroxyvitamin D3 a promising adjuvant for the improvement of SCIT.